Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $266.54 | 4 | 61.6% |
| Honoraria | $150.00 | 1 | 34.7% |
| Education | $16.23 | 1 | 3.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $150.00 | 1 | $0 (2020) |
| Janssen Biotech, Inc. | $127.28 | 2 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $125.40 | 1 | $0 (2023) |
| Ipsen Biopharmaceuticals, Inc | $16.23 | 1 | $0 (2024) |
| SOBI, INC | $13.86 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30.09 | 2 | Ipsen Biopharmaceuticals, Inc ($16.23) |
| 2023 | $252.68 | 3 | Janssen Biotech, Inc. ($127.28) |
| 2020 | $150.00 | 1 | Alexion Pharmaceuticals, Inc. ($150.00) |
All Payment Transactions
6 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/11/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 05/07/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/27/2023 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $9.51 | General |
| 05/25/2023 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $125.40 | General |
| Category: Oncology | ||||||
| 03/08/2023 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $117.77 | General |
| Category: Oncology | ||||||
| 09/15/2020 | Alexion Pharmaceuticals, Inc. | Ultomiris (Drug) | Honoraria | Cash or cash equivalent | $150.00 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 77 | 4,354 | 119,460 | $7.5M | $1.3M |
| 2022 | 45 | 1,155 | 24,407 | $1.7M | $374,126 |
All Medicare Procedures & Services
122 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 24 | 16,000 | $2.3M | $674,107 | 28.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 51 | 7,080 | $496,620 | $127,094 | 25.6% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 12 | 3,040 | $761,780 | $102,452 | 13.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 366 | 869 | $262,299 | $81,302 | 31.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 126 | 425 | $354,650 | $43,329 | 12.2% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 16 | 336 | $295,344 | $31,123 | 10.5% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 23 | 13,180 | $276,780 | $30,976 | 11.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 22 | 126 | $496,188 | $16,896 | 3.4% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 31 | 12,220 | $109,980 | $16,756 | 15.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 64 | 90 | $34,073 | $12,000 | 35.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 122 | 851 | $89,355 | $10,238 | 11.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 286 | 926 | $57,412 | $9,574 | 16.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 74 | 74 | $34,086 | $8,826 | 25.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 49 | 175 | $71,246 | $8,797 | 12.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 97 | 179 | $54,416 | $8,748 | 16.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 307 | 1,148 | $40,180 | $8,722 | 21.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 35 | 83 | $24,416 | $7,672 | 31.4% |
| J9025 | Injection, azacitidine, 1 mg | Office | 2023 | 21 | 21,010 | $411,376 | $7,303 | 1.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 54 | 119 | $24,219 | $7,052 | 29.1% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 20 | 384 | $67,200 | $6,611 | 9.8% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 17 | 87 | $6,090 | $6,350 | 104.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 23 | 111 | $27,657 | $6,272 | 22.7% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 22 | 15,300 | $91,800 | $6,266 | 6.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 82 | 88 | $15,888 | $5,227 | 32.9% |
| J1750 | Injection, iron dextran, 50 mg | Office | 2023 | 16 | 342 | $26,638 | $4,583 | 17.2% |
About Dr. Omer Ali, MD
Dr. Omer Ali, MD is a Hematology & Oncology healthcare provider based in Hampton, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/02/2016. The National Provider Identifier (NPI) number assigned to this provider is 1881057206.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Omer Ali, MD has received a total of $432.77 in payments from pharmaceutical and medical device companies, with $30.09 received in 2024. These payments were reported across 6 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($266.54).
As a Medicare-enrolled provider, Ali has provided services to 5,509 Medicare beneficiaries, totaling 143,867 services with total Medicare billing of $1.7M. Data is available for 2 years (2022–2023), covering 122 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Hampton, VA
- Active Since 04/02/2016
- Last Updated 06/29/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1881057206
Products in Payments
- Ultomiris (Drug) $150.00
- Nubeqa (Drug) $125.40
- TECVAYLI (Biological) $117.77
- Onivyde (Drug) $16.23
- DOPTELET (Drug) $13.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Hampton
Dr. Ruby Kochhar, Md, MD
Hematology & Oncology — Payments: $457,155
Mark Fleming, Md, MD
Hematology & Oncology — Payments: $85,915
Scott Kruger, Md, MD
Hematology & Oncology — Payments: $1,205
David Kobulnicky, Md, MD
Hematology & Oncology — Payments: $924.26
Taha Sheikh, Md, MD
Hematology & Oncology — Payments: $373.64